Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 49,611 |
|
|||||
| News | - | ||||||
| Day High | 2.67 | Low High |
|||||
| Day Low | 2.255 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Indaptus Therapeutics Inc | INDP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.14 | -5.62% | 2.35 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.45 | 2.255 | 2.67 | 2.35 | 2.49 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 259 | 49,611 | $ 2.42 | $ 119,931 | - | 1.56 - 4.08 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:35:37 | 1 | $ 2.27 | USD |
Indaptus Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 82.23M | 8.54M | - | 0 | -15.42M | -1.81 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Indaptus Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical INDP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.74 | 2.74 | 2.255 | 2.54 | 14,855 | -0.39 | -14.23% |
| 1 Month | 2.80 | 2.95 | 2.03 | 2.54 | 27,633 | -0.45 | -16.07% |
| 3 Months | 1.67 | 2.95 | 1.56 | 2.32 | 92,734 | 0.68 | 40.72% |
| 6 Months | 2.22 | 3.25 | 1.56 | 2.31 | 50,264 | 0.13 | 5.86% |
| 1 Year | 2.92 | 4.08 | 1.56 | 2.33 | 33,322 | -0.57 | -19.52% |
| 3 Years | 10.10 | 28.8299 | 1.25 | 9.31 | 466,795 | -7.75 | -76.73% |
| 5 Years | 10.10 | 28.8299 | 1.25 | 9.31 | 466,795 | -7.75 | -76.73% |
Indaptus Therapeutics Description
| Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. |
